Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)

← catalyst calendar

NCT05263206 · readout in 287 d

Sponsored by Sanofi (industry) · SNY — their whole pipeline →.

Phase

Phase 3

Status

Recruiting

Study type

Interventional

Design

Randomized · Quadruple · Treatment

Enrollment

284estimated

Sites

Countries

Argentina, Canada, China +10

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2022-02-15

actual

When the study began enrolling

Primary completion

2027-06-02

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2027-08-25

estimated

The whole study's end, after follow-up

First posted

2022-03-02

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-06

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Pruritus

Interventions

Drug: Dupilumab
Drug: Placebo
Drug: Fexofenadine (loratadine if not available)

Primary outcomes

what the primary-completion date above is the date OF

Study A: Proportion of participants with improvement (reduction) in weekly average of daily worst-itch numerical rating scale (WI-NRS) by ≥4 from baseline to Week 24

measured Baseline to Week 24

Study B: Proportion of participants with improvement (reduction) in weekly average of daily WI-NRS by ≥4 from baseline to Week 12

measured Baseline to Week 12

Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed